---

name: clinical-trial-agreement language: en description: >- Drafts U.S. clinical trial agreements governing sponsor–site–investigator relationships under FDA rules (21 CFR Parts 50, 56, 312) and ICH-GCP E6(R2). Use when drafting or negotiating CTAs, sponsor research agreements, or protocol-specific contracts for investigational drugs, devices, or biologics. tags:

• agreement
• drafting
• regulatory

---

Clinical Trial Agreement

Draft a protocol-specific CTA governing study conduct, compliance, data rights, payments, and risk allocation.

Quick Start

Gather before drafting:

1. Final or near-final protocol (number, version, phase, endpoints, schedule of events)
2. Investigator Brochure or device manual with current safety profile
3. Draft budget with FMV rationale and payment schedule
4. Site policies on contracting, IP, publication, and indemnification
5. Regulatory status: IND/IDE holder, IRB process, DSMB plan if any

Intake

Complete and confirm all fields before drafting.

Field	Req	Notes
Sponsor name/address	Y	Include parent or funding affiliate
Institution name/address	Y	Include hospital/academic entity
Principal Investigator	Y	Note if individual signature needed
Protocol title/number/version	Y	Attach as Exhibit A
Phase and design	Y	Randomized, blinded, placebo, etc.
Site enrollment target	Y	Min, max, or good-faith estimate
IND/IDE holder and number	Y	Sponsor vs institution
Investigational product	Y	Drug/device/biologic and comparators
Central lab and vendors	If appl.	Include data flows
Privacy model	Y	HIPAA auth vs waiver; de-ID plan
Insurance limits	Y	Sponsor and institution coverage
Publication plan	Y	Single-site vs multicenter
Governing law/venue	Y	State selection
Compensation model	Y	Per-subject, milestone, hybrid
Closeout and retention	Y	Record retention period

Agreement Sections

Section	Required Content
Parties and Recitals	All parties; protocol reference; regulatory framework
Definitions	Study, Protocol, Investigational Product, AE/SAE (21 CFR 312.32), GCP, Study Data, Confidential Information
Study Conduct	Protocol incorporation; amendment process; investigator independence; facilities/staffing
Sponsor Obligations	Product supply; training; monitoring; regulatory submissions; safety updates
Site/Investigator Obligations	IRB approval; informed consent (21 CFR 50.27); records; protocol adherence; safety reporting
Data and Records	Source data access; CRF completion; retention period
Budget and Payment	FMV structure; invoicing; screen failures; early withdrawals; withholding rights
Confidentiality and Privacy	Exceptions; HIPAA (45 CFR Parts 160, 164); de-identification
IP and Publications	Data/invention ownership; review windows; multicenter restrictions
Indemnification and Insurance	Mutual indemnity; product liability; limits; additional insureds
Term and Termination	For cause/convenience; subject safety; wind-down; survival
Dispute Resolution	Negotiation → mediation → arbitration/courts; injunctive relief
Admin	Notices, assignment, amendment, severability, independent contractor

Compliance Checklist

• IRB approval before study start and for amendments
• Informed consent meets 21 CFR Part 50
• IRB requirements per 21 CFR Part 56
• IND/IDE responsibilities per 21 CFR Part 312
• SAE reporting timelines defined; sponsor notification within 24 hours
• GCP reference to ICH E6(R2)
• Record retention ≥ 2 years after FDA approval or discontinuation
• HIPAA minimum necessary disclosure
• Conflict disclosure and exclusion/debarment status
• Anti-kickback and Stark Law compliance for compensation

Risk Tailoring

• High-risk product → higher insurance limits + enhanced safety monitoring
• Vulnerable populations → explicit consent safeguards
• Invasive procedures → explicit injury and compensation language

Exhibits

• A: Protocol
• B: Budget and payment schedule
• C: Schedule of events/procedures (if separate)

Pitfalls

• Use exact protocol identifiers and dates — do not paraphrase protocol constraints.
• Define AE/SAE per 21 CFR 312.32. Mark [VERIFY] if deviating.
• Never promise sponsor control over investigator medical judgment.
• Keep publication review windows time-bounded (30–60 days).
• Compensation must be FMV, not tied to outcomes or referrals.
• If state law mandates clinical trial injury coverage, add state-specific language. [VERIFY] if unsure.
• Preserve subject safety obligations post-termination (follow-up and reporting).